OrbiMed’s Alaunos Therapeutics TCRT Stock Holding History

OrbiMed’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-16,918	Closed	-$27.3M	–	150
2015 Q1	$27.3M	Buy	+16,918	New	+$25.1M	0.23%	69

Other funds holding TCRT

UOTTAIMCU

University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Third Point New York $2.08B AUM 27.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed's TCRT Position: Q2 2015 in Review

OrbiMed sold out of Alaunos Therapeutics (TCRT) in Q2 2015, closing a stake of 16,918 shares — an estimated $27.3M sold.

OrbiMed first reported a position in TCRT in Q1 2015 and held it in 1 quarter. The position peaked at $27.3M in Q1 2015. 156 funds tracked by Wall St. Rank hold TCRT as of Q2 2015.

OrbiMed reported no remaining Alaunos Therapeutics position as of Q2 2015 after selling out during the quarter.
OrbiMed sold 16,918 Alaunos Therapeutics shares in Q2 2015, an estimated $27.3M.
OrbiMed first reported a position in Alaunos Therapeutics in Q1 2015 and held it in 1 quarter.
OrbiMed's Alaunos Therapeutics position peaked at $27.3M in Q1 2015.
156 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2015.

Based on OrbiMed's 13F filing for Q2 2015, filed 14 Aug 2015.